Vigonvita Life Sciences Co (HKSE:02630) Research & Development: HK$ Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02630 Vigonvita Life Sciences Co Ltd HKSE:02630
8 GF Score
Price HK$90.00
! 2 Warning Signs
View Full Analysis

What is Vigonvita Life Sciences Co Research & Development?

Vigonvita Life Sciences Co HKSE:02630 +5.32% 8 Research & Development is HK$ Mil as of Dec. 2025. GuruFocus rates HKSE:02630 with a GF Score™ of 8/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Vigonvita Life Sciences Co's Research & Development for the six months ended in Dec. 2025 was HK$223.7 Mil. Vigonvita Life Sciences Co does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in Dec. 2025.

Vigonvita Life Sciences Co  (HKSE:02630) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Vigonvita Life Sciences Co Research & Development Related Terms

Vigonvita Life Sciences Co Research & Development Historical Data

* Premium members only.

The historical data trend for Vigonvita Life Sciences Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vigonvita Life Sciences Co Research & Development Chart

Vigonvita Life Sciences Co Annual Data
Trend Dec23 Dec24 Dec25
Research & Development
143.61 143.99 223.71

Vigonvita Life Sciences Co Semi-Annual Data
Dec23 Dec24 Dec25
Research & Development 143.61 143.99 223.71
HKSE:02630
8GF Score
Vigonvita Life Sciences Co Ltd HKSE:02630
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vigonvita Life Sciences Co Research & Development Calculation

This is the expense the company spent on research and development.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$ Mil mean?
Vigonvita Life Sciences Co (HKSE:02630) has a Research & Development of HK$ Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Vigonvita Life Sciences Co and its competitors.
Is Vigonvita Life Sciences Co's Research & Development too high?
Vigonvita Life Sciences Co's current Research & Development is HK$ Mil. Overall, Vigonvita Life Sciences Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Vigonvita Life Sciences Co's Research & Development compare to LLY and JNJ?
Vigonvita Life Sciences Co's Research & Development of HK$ Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Vigonvita Life Sciences Co and its competitors. Vigonvita Life Sciences Co's current Research & Development is HK$ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vigonvita Life Sciences Co stock overvalued right now?
Vigonvita Life Sciences Co (HKSE:02630) has a current Research & Development of HK$ Mil. The current Research & Development is HK$ Mil. Vigonvita Life Sciences Co's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Vigonvita Life Sciences Co (HKSE:02630), the current Research & Development is HK$ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vigonvita Life Sciences Co Business Description

Address No. 108, Yuxin Road, 8th Floor, Building A, Suzhou Industrial Park District, Suzhou, CHN, 215123
Vigonvita Life Sciences Co Ltd biopharmaceutical company. It is focused on innovation driven biopharmaceutical development, with a strategic emphasis on addressing unmet clinical needs in the treatment of neuropsychiatric, infectious, and andrological diseases. The company's core Products include LV232, anti-depression drug candidate, VV913: a novel investigational drug candidate for premature ejaculation and, VV116: an oral nucleoside analog with broad-spectrum antiviral potential. The company's operations are located in the PRC and Uzbekistan. Revenue is generated from the out-licensing and the sales of its pharmaceutical products.
8GF Score

Get the complete analysis for HKSE:02630

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$90.00
Price